You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab.
Thermo Fisher has also applied to the Japanese Ministry of Health, Labor, and Welfare to expand the use of the Oncomine Dx Target test in Japan.
Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
After DS-1062 demonstrated encouraging activity in lung cancer, the firm decided to add a cohort of TNBC patients whose tumors express TROP2.
Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.
The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.
Genetron's S5 sequencer is based on Thermo Fisher's Ion GeneStudio S5 instrument and is cleared for clinical use by China's NMPA.
The company will now initiate the dose escalation portion of a Phase I/II study and will enroll 90 NSCLC patients in the country.
The firm can now market the drug to Chinese patients with early-stage HER2-positive breast cancer.